Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression

[1]  G. Evan,et al.  Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma , 2020, Hepatology.

[2]  M. Allison,et al.  Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in non-alcoholic fatty liver disease. , 2020, Gastroenterology.

[3]  F. Nigsch,et al.  Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model , 2019, Hepatology communications.

[4]  E. Albano,et al.  Adaptive immunity: an emerging player in the progression of NAFLD , 2019, Nature Reviews Gastroenterology & Hepatology.

[5]  P. Escribá,et al.  Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues , 2019, International journal of molecular sciences.

[6]  Robert V Farese,et al.  Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids. , 2019, Molecular cell.

[7]  Z. Younossi,et al.  Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.

[8]  W. Wahli,et al.  Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity , 2018, Scientific Reports.

[9]  C. Sirlin,et al.  Acetyl‐CoA Carboxylase Inhibitor GS‐0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  Charlotte L. Scott,et al.  Macrophages and lipid metabolism , 2018, Cellular immunology.

[11]  M. Allison,et al.  Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption , 2018, Genome Biology.

[12]  Marju Orho-Melander,et al.  Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars , 2018, Diabetes Care.

[13]  A. Feldstein,et al.  Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.

[14]  T. Luedde,et al.  Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis , 2018, Hepatology.

[15]  R. Hammer,et al.  Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice[S] , 2018, Journal of Lipid Research.

[16]  H. Waldmann,et al.  The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival , 2018, Front. Immunol..

[17]  D. Samuel,et al.  Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients , 2017, Scientific Reports.

[18]  S. Davies,et al.  Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease , 2017, Hepatology.

[19]  S. Bellentani The epidemiology of non‐alcoholic fatty liver disease , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[20]  A. Kennedy,et al.  Role of lipids in the metabolism and activation of immune cells. , 2016, The Journal of nutritional biochemistry.

[21]  P. Bedossa,et al.  A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer , 2016, Journal of hepatology.

[22]  Q. Anstee,et al.  Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. , 2016, Annual review of pathology.

[23]  M. Orešič,et al.  Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .

[24]  M. Allison,et al.  Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD , 2015, Seminars in Liver Disease.

[25]  Eoin Fahy,et al.  Biomarkers of NAFLD progression: a lipidomics approach to an epidemic1[S] , 2015, Journal of Lipid Research.

[26]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[27]  T. Luedde,et al.  Pharmacological inhibition of the chemokine C‐C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly‐6C+ macrophage infiltration in mice , 2014, Hepatology.

[28]  M. Raspa,et al.  FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units , 2014, Laboratory animals.

[29]  T. Hibi,et al.  Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice , 2014, Hepatology.

[30]  C. Lelliott,et al.  Adaptive Changes of the Insig1/SREBP1/SCD1 Set Point Help Adipose Tissue to Cope With Increased Storage Demands of Obesity , 2013, Diabetes.

[31]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[32]  M. Vacca,et al.  Nuclear receptors in regenerating liver and hepatocellular carcinoma , 2013, Molecular and Cellular Endocrinology.

[33]  A. Moschetta,et al.  Hepatic‐specific activation of peroxisome proliferator‐activated receptor γ coactivator‐1β protects against steatohepatitis , 2013, Hepatology.

[34]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[35]  J. Fallowfield,et al.  Edinburgh Research Explorer Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis Differential Ly-6C expression identi fi es the recruited macrophage phenotype, which orchestrates the regression of murine liver fi brosis , 2022 .

[36]  H. Guillou,et al.  The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. , 2012, The Journal of clinical investigation.

[37]  G. Farrell,et al.  SREBP‐2: A link between insulin resistance, hepatic cholesterol, and inflammation in NASH , 2011, Journal of gastroenterology and hepatology.

[38]  C. Cooper,et al.  No association between polymorphisms in the INSIG1 gene and the risk of type 2 diabetes and related traits. , 2010, The American journal of clinical nutrition.

[39]  Antonio Vidal-Puig,et al.  An allostatic control of membrane lipid composition by SREBP1 , 2010, FEBS letters.

[40]  M. Olivier,et al.  INSIG1 influences obesity-related hypertriglyceridemia in humans , 2010, Journal of Lipid Research.

[41]  Michelle M Wiest,et al.  The plasma lipidomic signature of nonalcoholic steatohepatitis , 2009, Hepatology.

[42]  Xiaohui Xie,et al.  Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal binding to a new motif , 2009, Proceedings of the National Academy of Sciences.

[43]  S. Caldwell,et al.  Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[44]  J. Fernandez-Checa,et al.  Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. , 2009, Journal of hepatology.

[45]  A. Feldstein,et al.  Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease , 2009, Journal of Biological Chemistry.

[46]  Z. Younossi,et al.  Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. , 2008, Journal of hepatology.

[47]  C. Kendziorski,et al.  Publishes Results of a Wide Variety of Studies from Human and from Informative Model Systems with Physiological Genomics , 2003 .

[48]  Michelle M Wiest,et al.  A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.

[49]  N. Fausto,et al.  Liver regeneration , 2006, Hepatology.

[50]  R. Hammer,et al.  Schoenheimer effect explained--feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. , 2005, The Journal of clinical investigation.

[51]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[52]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[53]  H. Tsukamoto,et al.  Adipogenic Transcriptional Regulation of Hepatic Stellate Cells* , 2005, Journal of Biological Chemistry.

[54]  J. Doyle,et al.  Metabolic syndrome and robustness tradeoffs. , 2004, Diabetes.

[55]  Jinping Li,et al.  Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Hammer,et al.  Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. , 2004, The Journal of clinical investigation.

[57]  Jay D. Horton,et al.  Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus* , 1999, The Journal of Biological Chemistry.

[58]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[59]  R. Hammer,et al.  Blunted feedback suppression of SREBP processing by dietary cholesterol in transgenic mice expressing sterol-resistant SCAP(D443N). , 1998, The Journal of clinical investigation.

[60]  A. Hamsten,et al.  Human evidence for the involvement of insulin-induced gene 1 in the regulation of plasma glucose concentration , 2006, Diabetologia.

[61]  J. Goldstein,et al.  Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. , 2003, Molecular cell.

[62]  O. R-CH2-CH2-CH,et al.  FATTY acid oxidation. , 1946, Nutrition reviews.